Clinical Trial Update: E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy [NA]

View source ↗

Summary

The clinical trial evaluating estradiol (E2) and LDX for cognitive complaints after oophorectomy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• E2 (estradiol)
• LDX (lisdexamfetamine)

Snippet

Sponsor: University of Pennsylvania | Conditions: Planned RRSO | NA | Status: WITHDRAWN